What Happens When You Stop GLP-1 Medication: The Weight-Regain Evidence

GLP-1 ads sell the destination. Almost nobody advertises what happens if you get there and then stop. Two trials were specifically designed to answer that question — one for semaglutide, one for tirzepatide — and both point the same direction: obesity behaves like the chronic condition it is, and the drug's effect mostly depends on staying on the drug.

The semaglutide withdrawal data

The STEP 1 trial extension followed participants who had lost weight on semaglutide through week 68, then randomized them to continue the drug or switch to placebo, tracking outcomes to week 120 — roughly one year off treatment¹. The result: participants who stopped semaglutide regained 11.6 percentage points of body weight (on average) versus 1.9 percentage points for those who stayed on treatment, meaning most of the trial group who stopped gave back roughly two-thirds of what they'd lost within about a year¹. Cardiometabolic improvements — blood pressure, CRP, and glycemic markers that had gotten better through week 68 — mostly reverted back toward baseline by week 120, including patients who had reached normal blood sugar reverting to prediabetic ranges¹.

The tirzepatide withdrawal data

SURMOUNT-4 was built around the same question for tirzepatide. Participants completed a 36-week lead-in on tirzepatide, then were randomized to either continue the drug or switch to placebo for an additional 52 weeks (to week 88)². From week 36 to week 88, the group that continued tirzepatide lost an additional 5.5% of body weight on average; the group switched to placebo regained 14.0%² — a roughly 19-percentage-point gap between the two arms. Only 16.6% of the placebo group maintained at least 80% of their week-36 weight loss by week 88, compared with 89.5% of the group that stayed on tirzepatide². Over the full 88-week trial, continuous tirzepatide use produced a 25.3% average weight reduction versus 9.9% in the group that stopped partway through².

Why this happens

Neither trial framed this as a drug failing — it's closer to the drug's job ending when the drug stops. GLP-1 receptor agonists work by suppressing appetite and slowing gastric emptying; once the medication clears your system, the physiological signals that drove hunger before treatment tend to return. That's consistent with how these drugs are studied and labeled in the first place: the pivotal obesity trials for both semaglutide and tirzepatide ran on continuous, ongoing dosing, not a fixed course³⁴.

Both trials studied a full stop, not a taper

One nuance worth noting: both trials measured what happens when a patient moves directly from an active dose to placebo, not a gradual dose taper down to zero. Neither the STEP 1 extension nor SURMOUNT-4 tested whether tapering off more slowly changes the regain curve¹². If you're planning to stop for a non-medical reason — cost, side effects, or simply wanting a break — that's a reason to have the conversation with your prescriber rather than stopping cold on your own, since the published evidence doesn't tell us whether a slower wind-down would produce a gentler landing.

What this means for your planning

If a program frames GLP-1 treatment as a short "reset," the trial evidence doesn't support that framing — the withdrawal data suggests weight regain is the expected outcome, not the exception, once treatment stops without a maintenance plan. That reframes the cost conversation too: the real price of GLP-1 treatment isn't one month, it's the ongoing monthly rate for as long as you intend to stay on it, which is exactly the trap covered in how to spot a GLP-1 teaser-rate trap. It's also a reason to weigh a program's tolerability and titration flexibility as heavily as its price — see GLP-1 side effects: what the STEP and SURMOUNT trials actually reported — since a plan you can actually sustain matters more than a plan you quit early.

If you're planning to stop for pregnancy or another reason

Stopping isn't only a weight-regain question — timing matters for other reasons too, including the pre-conception washout window discussed in GLP-1 and pregnancy or breastfeeding: what the labels actually say. Any decision to stop should go through your prescriber, not a unilateral pause.

If cost is the real reason you're considering stopping

A lot of people who talk about stopping aren't doing it for medical reasons — they're doing it because the monthly bill became unsustainable. Before you let cost force a stop that the evidence says will likely reverse your progress, it's worth confirming you've actually found the best legitimate price available, including whether a manufacturer savings card applies to your situation; see do GLP-1 savings cards actually lower the price?. Switching to a lower-cost compounded option or a different provider is very often a better move than stopping outright — see the cheapest legit way to start GLP-1 for how to shop that trade-off.

Choosing for the long haul

Because these drugs are designed for sustained use, the provider decision is really a "can I afford and tolerate this for a year or more" decision, not a one-month trial. Compare ongoing, flat monthly pricing — not intro rates — on our semaglutide price board and tirzepatide price board, and check prescriber support for long-term dose management in our provider reviews.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.